This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents
Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Fox Chase Cancer Center
This presentation reviews current treatments for early-stage and relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma. Emerging therapies, including CAR T-cell therapy, along with patient selection criteria and toxicities unique to new treatments are addressed as well.
These activities, certified for CME/CE/CPE credit, are jointly provided by
in collaboration with